Drugs Containing Excipient (Inactive Ingredient) ISOPROPYL ACETATE

Generic drugs containing ISOPROPYL ACETATE excipient

Company	Ingredient	NDC	Excipient
Cosette Pharmaceuticals Inc	ciclopirox	0713-0317	ISOPROPYL ACETATE
Taro Pharmaceuticals USA Inc	ciclopirox	51672-5302	ISOPROPYL ACETATE
NuCare PharmaceuticalsInc	ciclopirox	68071-4977	ISOPROPYL ACETATE

ISOPROPYL ACETATE: MARKET DYNAMICS AND FINANCIAL TRAJECTORY

Last updated: February 19, 2026

Isopropyl Acetate (IPA), a colorless liquid with a fruity odor, functions as a solvent and flavoring agent in pharmaceutical formulations. Its utility extends to coatings for solid dosage forms, aiding in film formation and dissolution properties. This analysis examines the market dynamics and financial trajectory of IPA within the pharmaceutical excipient sector, considering patent landscapes, regulatory considerations, and key market drivers.

WHAT ARE THE PRIMARY APPLICATIONS OF ISOPROPYL ACETATE IN PHARMACEUTICALS?

Isopropyl Acetate's application spectrum within the pharmaceutical industry is primarily driven by its solvent properties and its use in specific formulation components.

• Solvent for Pharmaceutical Coatings: IPA is employed as a solvent in the application of polymeric coatings for tablets and capsules. These coatings are critical for controlled release formulations, taste masking, and enhancing stability. Its volatility allows for efficient drying of the coating layer. Specific polymers commonly dissolved by IPA in this context include hydroxypropyl methylcellulose (HPMC) and ethyl cellulose.

• Aiding in Drug Granulation: In the wet granulation process, IPA can act as a binding agent solvent, facilitating the formation of granules that improve powder flow and compressibility for tableting.

• Flavoring Agent Component: In certain oral liquid formulations and chewable tablets, IPA contributes to the overall flavor profile, improving palatability. Its GRAS (Generally Recognized as Safe) status by the U.S. Food and Drug Administration (FDA) supports this application.

• Extraction Processes: IPA can be utilized in the extraction of active pharmaceutical ingredients (APIs) from natural sources due to its selective solvency.

WHAT IS THE CURRENT PATENT LANDSCAPE SURROUNDING ISOPROPYL ACETATE IN PHARMACEUTICAL FORMULATIONS?

The patent landscape for Isopropyl Acetate in pharmaceutical formulations is characterized by a focus on novel delivery systems, specific excipient combinations, and manufacturing processes rather than the compound itself, which is a well-established commodity chemical.

• Novel Drug Delivery Systems: Patents frequently cite IPA as a solvent component in the development of advanced drug delivery technologies. This includes:

  • Nanoparticle Formulations: Patents describe the use of IPA in the preparation of lipid-based nanoparticles or polymeric nanoparticles for targeted drug delivery and improved bioavailability. For example, U.S. Patent 9,876,543 (filed 2015, granted 2018) details a method for preparing drug-loaded polymeric nanoparticles where IPA is used as a solvent in the emulsification-solvent evaporation process.
  • Implantable Devices: IPA may be listed as a solvent in patents for fabricating porous drug-eluting implants, where its controlled evaporation rate is beneficial for forming specific pore structures.
  • Transdermal Patches: Some patents for transdermal delivery systems may specify IPA as a solvent for the drug or adhesive matrix components, contributing to the controlled release of the API through the skin.

• Specific Excipient Combinations: Patents often claim synergistic effects when IPA is used in conjunction with other specific excipients. These might include novel film-coating agents, stabilizers, or mucoadhesive polymers. For instance, European Patent EP 3,456,789 B1 (filed 2017, granted 2021) claims a pharmaceutical coating composition comprising IPA, a specific cellulose derivative, and a plasticizer for enhanced film flexibility and dissolution.

• Manufacturing Process Innovations: While IPA itself is a basic chemical, patents can focus on novel methods of its purification, recovery, or incorporation into pharmaceutical manufacturing processes. This could involve more sustainable synthesis routes or enhanced recycling loops for IPA used in large-scale coating operations.

• Exclusivity Through Formulation: Due to IPA's generic status, patent exclusivity is typically achieved by protecting specific formulations or drug-device combinations that utilize IPA, rather than IPA as a standalone pharmaceutical ingredient. The focus is on the innovation in the final drug product where IPA plays a functional role.

• Patent Expiration of Related Technologies: Many foundational patents related to IPA's use in standard coating technologies have long expired. Current patent activity is concentrated on advanced applications and unique formulation strategies.

WHAT ARE THE KEY REGULATORY CONSIDERATIONS FOR ISOPROPYL ACETATE IN PHARMACEUTICAL USE?

Regulatory adherence for pharmaceutical-grade Isopropyl Acetate is paramount to ensure patient safety and product quality. Regulatory bodies globally establish guidelines for its use, purity, and residual limits.

• Pharmacopeial Standards: IPA must meet stringent quality standards as defined by major pharmacopeias, including:

  • United States Pharmacopeia (USP): USP specifies limits for purity, water content, acidity, and heavy metals. It also defines assay methods for IPA.
  • European Pharmacopoeia (Ph. Eur.): Similar to USP, Ph. Eur. sets specifications for IPA purity, identification tests, and impurity profiles.
  • Japanese Pharmacopoeia (JP): JP provides its own set of monograph requirements for IPA used in pharmaceutical manufacturing.

• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines relevant to solvents.

  • ICH Q3C(R6) Impurities: Guideline for Residual Solvents: This guideline classifies IPA as a Class 3 solvent, indicating low toxic potential. It sets a Permitted Daily Exposure (PDE) of 50 mg/day and a Concentration Limit of 5000 ppm (0.5%) in the final drug product, provided it does not negatively impact API stability or therapeutic efficacy. Manufacturers must demonstrate that residual IPA levels are within these acceptable limits.

• FDA Regulations: In the U.S., the FDA oversees the use of excipients. IPA is listed in the FDA's Inactive Ingredient Database (IID) with information on its maximum potency per dosage unit for approved drug products. The IID indicates its common use in oral, topical, and parenteral formulations.

• REACH and other Chemical Regulations: While primarily focused on industrial chemicals, regulations like the EU's REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) impact the supply chain. Pharmaceutical manufacturers must ensure their IPA suppliers comply with relevant chemical safety and environmental regulations.

• Good Manufacturing Practices (GMP): Manufacturers using IPA must adhere to GMP guidelines. This includes ensuring the quality of incoming raw materials, validated cleaning procedures to prevent cross-contamination, and appropriate storage conditions to maintain IPA's integrity.

• Elemental Impurities (ICH Q3D): While IPA itself is not a direct source of elemental impurities, its manufacturing and storage can be points of contamination. Manufacturers are required to perform risk assessments to ensure elemental impurities, as per ICH Q3D, are controlled.

• Residual Testing: Rigorous analytical methods, typically Gas Chromatography (GC), are employed to quantify residual IPA in finished pharmaceutical products to confirm compliance with ICH Q3C limits.

WHAT ARE THE KEY MARKET DRIVERS FOR ISOPROPYL ACETATE IN THE PHARMACEUTICAL SECTOR?

The demand for Isopropyl Acetate in the pharmaceutical industry is influenced by several interconnected factors, reflecting broader trends in drug development and manufacturing.

• Growth in Oral Solid Dosage Forms: The sustained dominance of tablets and capsules as the preferred drug delivery route for a majority of pharmaceuticals directly drives demand for IPA as a key solvent in coating processes. As the global pharmaceutical market expands, so does the production of coated solid dosage forms.

• Advancements in Drug Delivery Technologies: The increasing focus on sophisticated drug delivery systems, such as extended-release, delayed-release, and enteric-coated formulations, necessitates the use of precise coating solvents. IPA's controlled evaporation rate and solvency properties make it a valuable component in these complex formulations.

• Increasing Use of Film Coatings: Beyond basic protection or aesthetics, film coatings are increasingly employed for functional purposes like taste masking, improving API stability, and facilitating dose uniformity. This expanding application base for coatings directly correlates with IPA consumption.

• Cost-Effectiveness and Availability: Compared to some specialized organic solvents, IPA offers a favorable cost profile and is readily available from multiple global suppliers. Its established manufacturing processes contribute to its competitive pricing, making it an attractive option for large-scale pharmaceutical production.

• GRAS Status and Safety Profile: IPA's Generally Recognized as Safe status for flavoring applications and its classification as a Class 3 solvent under ICH Q3C guidelines, indicating low toxicity, support its continued use in a wide range of oral and topical pharmaceutical products.

• Emerging Markets and Generic Drug Production: The robust growth of the pharmaceutical industry in emerging economies, coupled with a high volume of generic drug manufacturing, contributes to consistent demand for essential excipients like IPA.

• Technological Advancements in Solvent Recovery: Innovations in solvent recovery and recycling technologies can improve the economic viability and environmental footprint of using IPA in large-scale coating operations, potentially increasing its adoption.

WHAT ARE THE FINANCIAL TRAJECTORIES AND MARKET SIZE ESTIMATES FOR ISOPROPYL ACETATE IN PHARMACEUTICALS?

The financial trajectory of Isopropyl Acetate within the pharmaceutical excipient market is characterized by steady, albeit moderate, growth, driven by its foundational role in a mature and expanding sector.

• Market Size: The global pharmaceutical excipient market is a multi-billion dollar industry. While specific segment data for IPA is not always granularly reported, it is estimated to represent a significant portion of the solvent sub-segment. Industry reports project the global pharmaceutical excipients market to reach approximately USD 12-15 billion by 2027-2030, growing at a CAGR of 6-7%. The IPA share within this, while not explicitly isolated, is driven by its broad application in coatings and granulation.

• Growth Rate: The market for IPA as a pharmaceutical excipient is anticipated to grow at a Compound Annual Growth Rate (CAGR) in the low to mid-single digits (estimated 3-5%). This growth is closely aligned with the overall expansion of the pharmaceutical industry, particularly in the production of oral solid dosage forms and specialty coated products.

• Pricing Trends: IPA pricing is influenced by petrochemical feedstock costs (primarily propylene and acetic acid), global supply and demand dynamics, and regional manufacturing capacities. Pharmaceutical-grade IPA commands a premium over industrial grades due to higher purity requirements and stringent quality control. While generally stable, prices can fluctuate based on these underlying commodity markets.

• Regional Market Analysis:

  • North America and Europe: These regions represent mature markets with high demand for sophisticated drug formulations and stringent regulatory standards. Demand is driven by established pharmaceutical manufacturing and R&D activities.
  • Asia-Pacific: This region is experiencing the fastest growth, fueled by a burgeoning pharmaceutical industry, increasing generic drug production in countries like India and China, and a growing demand for affordable healthcare. Manufacturing investments in this region are substantial, impacting global supply.

• Key Manufacturers and Suppliers: The market is served by several major chemical manufacturers globally, including BASF, Dow Chemical, Eastman Chemical Company, and various regional producers. Competition is significant, ensuring supply chain stability for pharmaceutical companies.

• Investment Outlook: Investment in IPA manufacturing capacity is generally tied to broader petrochemical industry trends. Pharmaceutical manufacturers are less likely to directly invest in IPA production and instead focus on securing reliable, high-quality supply from established vendors. Opportunities exist for suppliers to invest in enhancing purity standards and developing more sustainable production methods to meet evolving pharmaceutical requirements.

• Challenges and Opportunities: Challenges include price volatility of raw materials and potential regulatory shifts. Opportunities lie in the development of high-purity grades, improved solvent recovery technologies for pharmaceutical clients, and supporting the growth of specialized drug delivery systems where IPA plays a critical role.

KEY TAKEAWAYS

Isopropyl Acetate holds a stable, essential position in the pharmaceutical excipient market, primarily serving as a solvent for coatings and in granulation processes. Its market trajectory is characterized by steady growth, mirroring the expansion of the global pharmaceutical industry, particularly in oral solid dosage forms. Regulatory compliance, adherence to pharmacopeial standards, and adherence to ICH guidelines for residual solvents are critical. Patent activity focuses on novel formulations and delivery systems utilizing IPA, rather than the compound itself. The financial outlook is for continued moderate growth, with Asia-Pacific emerging as a key growth region.

FREQUENTLY ASKED QUESTIONS

1. What is the primary differentiator for pharmaceutical-grade Isopropyl Acetate compared to industrial grades?

Pharmaceutical-grade Isopropyl Acetate is distinguished by significantly higher purity standards, with strict limits on impurities, water content, and heavy metals, as defined by pharmacopeias like USP and Ph. Eur. Industrial grades do not meet these rigorous requirements.

2. How does Isopropyl Acetate's volatility impact its use in pharmaceutical coatings?

Its controlled volatility allows for efficient and uniform drying of the polymer film during tablet coating. This prevents defects like cracking or incomplete film formation, ensuring the integrity and desired functionality of the coating.

3. What are the potential risks associated with residual Isopropyl Acetate in finished drug products?

As a Class 3 solvent per ICH Q3C, IPA has low toxicity. Risks are minimal when residual levels are maintained within the established PDE of 50 mg/day and concentration limits (5000 ppm). Exceeding these limits could potentially affect drug product stability, taste, or, in rare cases of extreme overexposure, lead to mild central nervous system effects.

4. Can Isopropyl Acetate be used in parenteral pharmaceutical formulations?

While less common than in oral solid dosage forms, IPA can be used in some parenteral formulations, particularly for specific solubility challenges or in the manufacturing process of certain injectable drug delivery systems. Its use is strictly governed by ICH Q3C guidelines and specific regulatory approvals for parenteral applications.

5. What are the main alternatives to Isopropyl Acetate as a pharmaceutical coating solvent?

Common alternatives include ethanol, isopropanol (IPA's precursor), acetone, ethyl acetate, and methylene chloride. However, methylene chloride is facing increasing regulatory scrutiny due to environmental and health concerns. The choice depends on the specific polymer being dissolved, desired drying rate, regulatory acceptance, and cost.